RU2006115558A - Ингибиторы сериновых протеаз, особенно hcv ns3-ns4a протеазы - Google Patents
Ингибиторы сериновых протеаз, особенно hcv ns3-ns4a протеазы Download PDFInfo
- Publication number
- RU2006115558A RU2006115558A RU2006115558/04A RU2006115558A RU2006115558A RU 2006115558 A RU2006115558 A RU 2006115558A RU 2006115558/04 A RU2006115558/04 A RU 2006115558/04A RU 2006115558 A RU2006115558 A RU 2006115558A RU 2006115558 A RU2006115558 A RU 2006115558A
- Authority
- RU
- Russia
- Prior art keywords
- ring
- aliphatic group
- cycloalkyl
- heteroaryl
- aryl
- Prior art date
Links
- 0 CCCCC([C@@](C)CCC)[C@@]1*2(CCCC2)C1C Chemical compound CCCCC([C@@](C)CCC)[C@@]1*2(CCCC2)C1C 0.000 description 6
- ZPRZWFMMXITIEN-UHFFFAOYSA-N CC(C(C1)N(C)C(C2)C1C1C2CCCC1)=O Chemical compound CC(C(C1)N(C)C(C2)C1C1C2CCCC1)=O ZPRZWFMMXITIEN-UHFFFAOYSA-N 0.000 description 1
- PSYGDLIDUQPOKY-UHFFFAOYSA-N CC(C(C1)N(C)CC1OCc1cc(cccc2)c2cc1)=O Chemical compound CC(C(C1)N(C)CC1OCc1cc(cccc2)c2cc1)=O PSYGDLIDUQPOKY-UHFFFAOYSA-N 0.000 description 1
- MSALOQXDUIXDDG-UHFFFAOYSA-N CC(C(C1)N(C)CC1OCc1cccc2c1cccc2)=O Chemical compound CC(C(C1)N(C)CC1OCc1cccc2c1cccc2)=O MSALOQXDUIXDDG-UHFFFAOYSA-N 0.000 description 1
- DNCOHZODLHDVGD-UHFFFAOYSA-N CC(C(C1)N(C)CC1OCc1ccccc1)=O Chemical compound CC(C(C1)N(C)CC1OCc1ccccc1)=O DNCOHZODLHDVGD-UHFFFAOYSA-N 0.000 description 1
- CJJIOQWQNCHWOP-MRTLOADZSA-N CC(C(C1)N(C)C[C@@H]1[n](nc1-c2ccccc2)nc1-c1ccccc1)=O Chemical compound CC(C(C1)N(C)C[C@@H]1[n](nc1-c2ccccc2)nc1-c1ccccc1)=O CJJIOQWQNCHWOP-MRTLOADZSA-N 0.000 description 1
- WTYLAGIFKVNSEQ-UHFFFAOYSA-N CC(C(C=CC1CC2NC)N1C2=O)=O Chemical compound CC(C(C=CC1CC2NC)N1C2=O)=O WTYLAGIFKVNSEQ-UHFFFAOYSA-N 0.000 description 1
- PENAODPZFZITCT-UHFFFAOYSA-N CC(C(CC1)N(C2)C1CCC2NC)=O Chemical compound CC(C(CC1)N(C2)C1CCC2NC)=O PENAODPZFZITCT-UHFFFAOYSA-N 0.000 description 1
- PRJWZCFBRYCMOE-UHFFFAOYSA-N CC(C(CC1)N(C2=O)N1CCCN2NC)=O Chemical compound CC(C(CC1)N(C2=O)N1CCCN2NC)=O PRJWZCFBRYCMOE-UHFFFAOYSA-N 0.000 description 1
- VMTLDTWEMMJNCU-UHFFFAOYSA-N CC(C(CC12)N(C)C1NC1C2NCCC1)=O Chemical compound CC(C(CC12)N(C)C1NC1C2NCCC1)=O VMTLDTWEMMJNCU-UHFFFAOYSA-N 0.000 description 1
- UPXMTVUDVIMOMT-UHFFFAOYSA-N CC(C(CC12)N(C)C1Nc1c2cccn1)=O Chemical compound CC(C(CC12)N(C)C1Nc1c2cccn1)=O UPXMTVUDVIMOMT-UHFFFAOYSA-N 0.000 description 1
- MPZORVHGOJJCBE-UHFFFAOYSA-N CC(C(CC12)N(C)C1Nc1c2ccnc1)=O Chemical compound CC(C(CC12)N(C)C1Nc1c2ccnc1)=O MPZORVHGOJJCBE-UHFFFAOYSA-N 0.000 description 1
- APKLCLCQXYADRE-UHFFFAOYSA-N CC(C(CC12)N(C)C1Nc1c2cncc1)=O Chemical compound CC(C(CC12)N(C)C1Nc1c2cncc1)=O APKLCLCQXYADRE-UHFFFAOYSA-N 0.000 description 1
- YPQOSOMZNCTZIV-UHFFFAOYSA-N CC(C(CCC1)N(C2=O)N1CCCN2NC)=O Chemical compound CC(C(CCC1)N(C2=O)N1CCCN2NC)=O YPQOSOMZNCTZIV-UHFFFAOYSA-N 0.000 description 1
- WCWAJWJVMPOYLI-UHFFFAOYSA-N CC(C(CCC1=NC=C2NC)N1C2=O)=O Chemical compound CC(C(CCC1=NC=C2NC)N1C2=O)=O WCWAJWJVMPOYLI-UHFFFAOYSA-N 0.000 description 1
- KVVPVHPVSILHSX-UHFFFAOYSA-N CC(C(CCCC1=NC=C2NC)N1C2=O)=O Chemical compound CC(C(CCCC1=NC=C2NC)N1C2=O)=O KVVPVHPVSILHSX-UHFFFAOYSA-N 0.000 description 1
- PMGQDOGUGBNIHE-UHFFFAOYSA-N CC(C(CNC1CC2NC)N1C2=O)=O Chemical compound CC(C(CNC1CC2NC)N1C2=O)=O PMGQDOGUGBNIHE-UHFFFAOYSA-N 0.000 description 1
- JTZRPWNKLZJZFB-UHFFFAOYSA-N CC(C(COC1CC2NC)N1C2=O)=O Chemical compound CC(C(COC1CC2NC)N1C2=O)=O JTZRPWNKLZJZFB-UHFFFAOYSA-N 0.000 description 1
- AUFZRNJYCVYWAN-UHFFFAOYSA-N CC(C(CSC1CC2NC)N1C2=O)=O Chemical compound CC(C(CSC1CC2NC)N1C2=O)=O AUFZRNJYCVYWAN-UHFFFAOYSA-N 0.000 description 1
- SJEZIHPCSCLGGK-UHFFFAOYSA-N CC(C1N(C)C2NC(CCCC3)C3C2C1)=O Chemical compound CC(C1N(C)C2NC(CCCC3)C3C2C1)=O SJEZIHPCSCLGGK-UHFFFAOYSA-N 0.000 description 1
- WYVCVCNDHCXMPG-UHFFFAOYSA-N CC(C1N(C)C2NC(CCNC3)C3C2C1)=O Chemical compound CC(C1N(C)C2NC(CCNC3)C3C2C1)=O WYVCVCNDHCXMPG-UHFFFAOYSA-N 0.000 description 1
- LERQTEOOMKVSKM-UHFFFAOYSA-N CC(C1N(C)C2NC(CNCC3)C3C2C1)=O Chemical compound CC(C1N(C)C2NC(CNCC3)C3C2C1)=O LERQTEOOMKVSKM-UHFFFAOYSA-N 0.000 description 1
- GZBPEQHESSJRPW-UHFFFAOYSA-N CC(C1N(C)C2NC3NCCCC3C2C1)=O Chemical compound CC(C1N(C)C2NC3NCCCC3C2C1)=O GZBPEQHESSJRPW-UHFFFAOYSA-N 0.000 description 1
- LEWRGDPKNRUOBT-UHFFFAOYSA-N CC(C1N(C)C2Nc3cccnc3C2C1)=O Chemical compound CC(C1N(C)C2Nc3cccnc3C2C1)=O LEWRGDPKNRUOBT-UHFFFAOYSA-N 0.000 description 1
- BVVCPCIUYCENAS-UHFFFAOYSA-N CC(C1N(C)C2OC(CCCC3)C3C2C1)=O Chemical compound CC(C1N(C)C2OC(CCCC3)C3C2C1)=O BVVCPCIUYCENAS-UHFFFAOYSA-N 0.000 description 1
- FDIKJQSLNVXCGP-UHFFFAOYSA-N CC(C1N(C)C2SC(CCCC3)C3C2C1)=O Chemical compound CC(C1N(C)C2SC(CCCC3)C3C2C1)=O FDIKJQSLNVXCGP-UHFFFAOYSA-N 0.000 description 1
- UGXICRZJJBNLES-UHFFFAOYSA-N CC(C1N(C)CC2C1C1CC2CC1)=O Chemical compound CC(C1N(C)CC2C1C1CC2CC1)=O UGXICRZJJBNLES-UHFFFAOYSA-N 0.000 description 1
- AZZDJWMTNMLXTE-UHFFFAOYSA-N CC(C1N(C)CC2C1C1NC2CC1)=O Chemical compound CC(C1N(C)CC2C1C1NC2CC1)=O AZZDJWMTNMLXTE-UHFFFAOYSA-N 0.000 description 1
- DTXRKOMFJJIHQQ-UHFFFAOYSA-N CC(C1N(C)CC2C1C1SC2CC1)=O Chemical compound CC(C1N(C)CC2C1C1SC2CC1)=O DTXRKOMFJJIHQQ-UHFFFAOYSA-N 0.000 description 1
- MBYLCPNYNFPEGO-UHFFFAOYSA-N CC(C1N(C)CC2C1SCCC2)=O Chemical compound CC(C1N(C)CC2C1SCCC2)=O MBYLCPNYNFPEGO-UHFFFAOYSA-N 0.000 description 1
- OEKQXFLIHRRQRX-UHFFFAOYSA-N CC(C1N(C)Cc2c(cc3)[o]c3c12)=O Chemical compound CC(C1N(C)Cc2c(cc3)[o]c3c12)=O OEKQXFLIHRRQRX-UHFFFAOYSA-N 0.000 description 1
- NWTVYVJSHUOOCE-UHFFFAOYSA-N CC(C1N(CC(CC2)NC)C2NC1)=O Chemical compound CC(C1N(CC(CC2)NC)C2NC1)=O NWTVYVJSHUOOCE-UHFFFAOYSA-N 0.000 description 1
- APHUYPADINESLM-UHFFFAOYSA-N CC(C1N(CC(CC2)NC)C2OC1)=O Chemical compound CC(C1N(CC(CC2)NC)C2OC1)=O APHUYPADINESLM-UHFFFAOYSA-N 0.000 description 1
- ULSXBYJFOPUNQS-UHFFFAOYSA-N CC(C1N(CC(CC2)NC)C2SC1)=O Chemical compound CC(C1N(CC(CC2)NC)C2SC1)=O ULSXBYJFOPUNQS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51015603P | 2003-10-10 | 2003-10-10 | |
US60/510,156 | 2003-10-10 | ||
US51376803P | 2003-10-23 | 2003-10-23 | |
US60/513,768 | 2003-10-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2006115558A true RU2006115558A (ru) | 2007-11-20 |
Family
ID=34467967
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006115558/04A RU2006115558A (ru) | 2003-10-10 | 2004-10-08 | Ингибиторы сериновых протеаз, особенно hcv ns3-ns4a протеазы |
Country Status (14)
Families Citing this family (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ298749B6 (cs) * | 1996-10-18 | 2008-01-16 | Vertex Pharmaceuticals Incorporated | Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem |
AU2001251165A1 (en) * | 2000-04-03 | 2001-10-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
TW200510391A (en) * | 2003-04-11 | 2005-03-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US7176208B2 (en) | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
US7109172B2 (en) | 2003-07-18 | 2006-09-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
MY148123A (en) * | 2003-09-05 | 2013-02-28 | Vertex Pharma | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
AR045769A1 (es) | 2003-09-18 | 2005-11-09 | Vertex Pharma | Inhibidores de las serina proteasas, particularmente, la proteasa ns3-ns4a del vhc (virus hepatitis c) |
AU2004282148A1 (en) * | 2003-10-10 | 2005-04-28 | Vertex Pharmaceuticals Incoporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
PL1677827T3 (pl) * | 2003-10-27 | 2009-06-30 | Vertex Pharma | Połączenia do leczenia HCV |
JP2008505849A (ja) * | 2004-02-04 | 2008-02-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼ、特に、hcv、ns3−ns4aプロテアーゼの阻害剤 |
US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7592336B2 (en) | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
AU2006276246B2 (en) | 2005-07-25 | 2012-09-27 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis C virus replication |
ES2401661T3 (es) * | 2005-08-02 | 2013-04-23 | Vertex Pharmaceuticals Incorporated | Inhibidores de serina proteasas |
US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
US7964624B1 (en) * | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
UA93990C2 (ru) | 2005-10-11 | 2011-03-25 | Интермюн, Инк. | Соединения и способ ингибирования репликации вируса гепатита c |
US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CA2643688A1 (en) | 2006-02-27 | 2007-08-30 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
KR20080112303A (ko) | 2006-03-16 | 2008-12-24 | 버텍스 파마슈티칼스 인코포레이티드 | 중수소화 c형 간염 프로테아제 억제제 |
MX2008013119A (es) * | 2006-04-11 | 2008-10-21 | Novartis Ag | Inhibidores de hcv/vih y sus usos. |
AU2007253819B2 (en) | 2006-05-23 | 2011-02-17 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
KR20090024834A (ko) * | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | C형 간염 바이러스 복제의 신규 억제제 |
WO2008008776A2 (en) | 2006-07-11 | 2008-01-17 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CA2677487A1 (en) | 2007-02-09 | 2008-08-14 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
WO2008106058A2 (en) * | 2007-02-27 | 2008-09-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
US8759353B2 (en) | 2007-02-27 | 2014-06-24 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
NZ581606A (en) * | 2007-05-03 | 2012-06-29 | Intermune Inc | Novel macrocyclic inhibitors of hepatitis c virus replication |
EA200971041A1 (ru) | 2007-05-10 | 2010-08-30 | Интермьюн, Инк. | Новые пептидные ингибиторы репликации вируса гепатита с |
US8492546B2 (en) | 2007-08-30 | 2013-07-23 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
US8419332B2 (en) * | 2007-10-19 | 2013-04-16 | Atlas Bolt & Screw Company Llc | Non-dimpling fastener |
US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
US8778877B2 (en) | 2007-12-21 | 2014-07-15 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
US8309685B2 (en) | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
TW201518507A (zh) | 2007-12-21 | 2015-05-16 | Celgene Avilomics Res Inc | Hcv蛋白酶抑制劑及其用途(二) |
EP2252311A1 (en) * | 2008-01-24 | 2010-11-24 | Enanta Pharmaceuticals, Inc. | Heteroaryl-containing tripeptide hcv serine protease inhibitors |
US8003659B2 (en) * | 2008-02-04 | 2011-08-23 | Indenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
KR20110005869A (ko) * | 2008-04-15 | 2011-01-19 | 인터뮨, 인크. | C형 간염 바이러스 복제의 신규한 마크로사이클릭 억제제 |
US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8044023B2 (en) | 2008-05-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
TW201004632A (en) | 2008-07-02 | 2010-02-01 | Idenix Pharmaceuticals Inc | Compounds and pharmaceutical compositions for the treatment of viral infections |
US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN102216321A (zh) * | 2008-10-15 | 2011-10-12 | 因特蒙公司 | 治疗性抗病毒肽 |
US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8321151B2 (en) | 2008-12-30 | 2012-11-27 | The Invention Science Fund I, Llc | Computational methods and systems for treatment in relation to modulation of CYP450 enzyme activity |
US8073633B2 (en) * | 2008-12-30 | 2011-12-06 | The Invention Science Fund I, Llc | Computational methods and systems for suggesting modulators of CYP450 as treatment options |
US8315815B2 (en) | 2008-12-30 | 2012-11-20 | The Invention Science Fund I, Llc | Computational methods and systems for suggesting modulators of CYP450 as treatment options |
US8102720B2 (en) * | 2009-02-02 | 2012-01-24 | Qualcomm Incorporated | System and method of pulse generation |
AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
WO2010101967A2 (en) | 2009-03-04 | 2010-09-10 | Idenix Pharmaceuticals, Inc. | Phosphothiophene and phosphothiazole hcv polymerase inhibitors |
TW201040181A (en) | 2009-04-08 | 2010-11-16 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
US20110182850A1 (en) * | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
WO2011017389A1 (en) | 2009-08-05 | 2011-02-10 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv |
CN105001302A (zh) * | 2009-09-28 | 2015-10-28 | 英特穆恩公司 | C型肝炎病毒复制的环肽抑制剂 |
TW201116540A (en) * | 2009-10-01 | 2011-05-16 | Intermune Inc | Therapeutic antiviral peptides |
US20110117055A1 (en) | 2009-11-19 | 2011-05-19 | Macdonald James E | Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds |
AR079528A1 (es) | 2009-12-18 | 2012-02-01 | Idenix Pharmaceuticals Inc | Inhibidores de arileno o heteroarileno 5,5-fusionado del virus de la hepatitis c |
MX2012011222A (es) | 2010-04-01 | 2013-01-18 | Centre Nat Rech Scient | Compuestos y composiciones farmaceuticas para el tratamiento de infecciones virales. |
US9353100B2 (en) | 2011-02-10 | 2016-05-31 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
CA2843324A1 (en) | 2011-03-31 | 2012-11-15 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
AR088441A1 (es) | 2011-09-12 | 2014-06-11 | Idenix Pharmaceuticals Inc | Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales |
EP2755985B1 (en) | 2011-09-12 | 2017-11-01 | Idenix Pharmaceuticals LLC | Compounds and pharmaceutical compositions for the treatment of viral infections |
AR089650A1 (es) | 2011-10-14 | 2014-09-10 | Idenix Pharmaceuticals Inc | Fosfatos 3,5-ciclicos sustituidos de compuestos de nucleotido de purina y composiciones farmaceuticas para el tratamiento de infecciones virales |
WO2013082476A1 (en) | 2011-11-30 | 2013-06-06 | Emory University | Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections |
US20130217644A1 (en) | 2012-02-13 | 2013-08-22 | Idenix Pharmaceuticals, Inc. | Pharmaceutical Compositions of 2'-C-Methyl-Guanosine, 5'-[2[(3-Hydroxy-2,2-Dimethyl-1-Oxopropyl)Thio]Ethyl N-(Phenylmethyl)Phosphoramidate] |
WO2013177188A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
US9296778B2 (en) | 2012-05-22 | 2016-03-29 | Idenix Pharmaceuticals, Inc. | 3′,5′-cyclic phosphate prodrugs for HCV infection |
PE20150132A1 (es) | 2012-05-22 | 2015-02-14 | Idenix Pharmaceuticals Inc | Compuestos d-aminoacidos para enfermedad hepatica |
AP2015008384A0 (en) | 2012-10-08 | 2015-04-30 | Univ Montpellier Ct Nat De La Rech Scient | 2'-Chloro nucleoside analogs for hcv infection |
ES2613766T3 (es) | 2012-10-19 | 2017-05-25 | Bristol-Myers Squibb Company | Derivados de carbamato de hexadecahidrociclopropa(e)pirrolo(1,2-a)(1,4)diazaciclopentadecinilo sustituidos con 9-metilo como inhibidores de la proteasa no estructural 3 (NS3) para el tratamiento de infecciones del virus de la hepatitis C |
US20140112886A1 (en) | 2012-10-19 | 2014-04-24 | Idenix Pharmaceuticals, Inc. | Dinucleotide compounds for hcv infection |
WO2014066239A1 (en) | 2012-10-22 | 2014-05-01 | Idenix Pharmaceuticals, Inc. | 2',4'-bridged nucleosides for hcv infection |
US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2914598B1 (en) | 2012-11-02 | 2017-10-18 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9409943B2 (en) | 2012-11-05 | 2016-08-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US20140140951A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-Alanine Ester of Rp-Nucleoside Analog |
US20140140952A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-Alanine Ester of Sp-Nucleoside Analog |
US9211300B2 (en) | 2012-12-19 | 2015-12-15 | Idenix Pharmaceuticals Llc | 4′-fluoro nucleosides for the treatment of HCV |
WO2014137930A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | Thiophosphate nucleosides for the treatment of hcv |
US9309275B2 (en) | 2013-03-04 | 2016-04-12 | Idenix Pharmaceuticals Llc | 3′-deoxy nucleosides for the treatment of HCV |
JP6342922B2 (ja) | 2013-03-07 | 2018-06-13 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | C型肝炎ウイルス阻害剤 |
WO2014165542A1 (en) | 2013-04-01 | 2014-10-09 | Idenix Pharmaceuticals, Inc. | 2',4'-fluoro nucleosides for the treatment of hcv |
EP3004130B1 (en) | 2013-06-05 | 2019-08-07 | Idenix Pharmaceuticals LLC. | 1',4'-thio nucleosides for the treatment of hcv |
WO2015017713A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
EP3046924A1 (en) | 2013-09-20 | 2016-07-27 | IDENIX Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
WO2015061683A1 (en) | 2013-10-25 | 2015-04-30 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv |
US20160271162A1 (en) | 2013-11-01 | 2016-09-22 | Idenix Pharmacueticals, Llc | D-alanine phosphoramide pronucleotides of 2'-methyl 2'-fluro guanosine nucleoside compounds for the treatment of hcv |
EP3074399A1 (en) | 2013-11-27 | 2016-10-05 | Idenix Pharmaceuticals LLC | 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection |
EP3083654A1 (en) | 2013-12-18 | 2016-10-26 | Idenix Pharmaceuticals LLC | 4'-or nucleosides for the treatment of hcv |
EP2899207A1 (en) | 2014-01-28 | 2015-07-29 | Amikana.Biologics | New method for testing HCV protease inhibition |
WO2015134561A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection |
US20170066779A1 (en) | 2014-03-05 | 2017-03-09 | Idenix Pharmaceuticals Llc | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
WO2015134780A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv |
WO2015161137A1 (en) | 2014-04-16 | 2015-10-22 | Idenix Pharmaceuticals, Inc. | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
JP6740256B2 (ja) | 2015-02-13 | 2020-08-12 | オックスフォード ドラッグ デザイン リミテッド | アミノアシルtRNAシンテターゼ阻害薬としての新規なN−アシル−アリールスルホンアミド誘導体 |
CR20180413A (es) | 2016-02-05 | 2018-12-04 | Denali Therapeutics Inc | Inhibidores de la proteína quinasa 1 que interactua con el receptor |
GB201617064D0 (en) | 2016-10-07 | 2016-11-23 | Inhibox Limited And Latvian Institute Of Organic Synthesis The | Compounds and their therapeutic use |
EP3552017B1 (en) | 2016-12-09 | 2022-02-23 | Denali Therapeutics Inc. | Compounds useful as ripk1 inhibitors |
KR20210098504A (ko) | 2018-12-04 | 2021-08-10 | 브리스톨-마이어스 스큅 컴퍼니 | 다중 동위원소체 반응 모니터링에 의한 샘플내 보정 곡선을 사용한 분석 방법 |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2174992T3 (es) | 1992-12-29 | 2002-11-16 | Abbott Lab | Productos intermediarios para la obtencion de compuestos inhibidores de proteasas retrovirales. |
IL110752A (en) | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
US5559158A (en) | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
IL111991A (en) | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
HUT72440A (en) * | 1994-03-31 | 1996-04-29 | Bristol Myers Squibb Co | Imidazole-containing inhibitors of farnesyl protein transferase and pharmaceutical compositions containing them |
US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
SK286662B6 (sk) | 1996-04-23 | 2009-03-05 | Vertex Pharmaceuticals Incorporated | Deriváty močoviny, farmaceutické prostriedky, ktoré ich obsahujú, a ich použitie ako inhibítorov aktivity IMPDH enzýmu |
AU2933797A (en) | 1996-05-10 | 1997-12-05 | Schering Corporation | Synthetic inhibitors of hepatitis c virus ns3 protease |
CZ298749B6 (cs) * | 1996-10-18 | 2008-01-16 | Vertex Pharmaceuticals Incorporated | Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
ATE244717T1 (de) | 1997-03-14 | 2003-07-15 | Vertex Pharma | Inhibitoren des impdh-enzyms |
GB9707659D0 (en) | 1997-04-16 | 1997-06-04 | Peptide Therapeutics Ltd | Hepatitis C NS3 Protease inhibitors |
HUP0004853A3 (en) | 1997-08-11 | 2001-12-28 | Boehringer Ingelheim Ca Ltd | Hepatitis c inhibitor peptides, process for preparation thereof, pharmaceutical compositions comprising thereof, their use and their intermediates |
JP4452401B2 (ja) | 1997-08-11 | 2010-04-21 | ベーリンガー インゲルハイム (カナダ) リミテッド | C型肝炎ウイルス阻害ペプチドアナログ |
IT1299134B1 (it) | 1998-02-02 | 2000-02-29 | Angeletti P Ist Richerche Bio | Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi |
EP1066247B1 (en) | 1998-03-31 | 2006-11-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
GB9812523D0 (en) | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
DE19836514A1 (de) | 1998-08-12 | 2000-02-17 | Univ Stuttgart | Modifikation von Engineeringpolymeren mit N-basischen Gruppe und mit Ionenaustauschergruppen in der Seitenkette |
GB9825946D0 (en) | 1998-11-26 | 1999-01-20 | Angeletti P Ist Richerche Bio | Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease |
NZ514540A (en) | 1999-03-19 | 2003-11-28 | Vertex Pharma | Phenyl derivative useful as inhibitors of IMPDH enzyme |
UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
WO2001007407A1 (en) | 1999-07-26 | 2001-02-01 | Bristol-Myers Squibb Pharma Company | Lactam inhibitors of hepatitis c virus ns3 protease |
US7122627B2 (en) | 1999-07-26 | 2006-10-17 | Bristol-Myers Squibb Company | Lactam inhibitors of Hepatitis C virus NS3 protease |
US6699855B2 (en) | 2000-02-29 | 2004-03-02 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus NS3 protease |
AU2001251165A1 (en) * | 2000-04-03 | 2001-10-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
EP1268525B1 (en) | 2000-04-05 | 2008-12-31 | Schering Corporation | Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties |
CN1432022A (zh) | 2000-04-19 | 2003-07-23 | 先灵公司 | 含有烷基和芳基丙氨酸p2部分的丙型肝炎病毒的大环ns3-丝氨酸蛋白酶抑制剂 |
AR034127A1 (es) | 2000-07-21 | 2004-02-04 | Schering Corp | Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento |
MXPA03000626A (es) | 2000-07-21 | 2004-07-30 | Schering Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c. |
DE60141608D1 (de) | 2000-07-21 | 2010-04-29 | Dendreon Corp | Peptide als inhibitoren der ns3-serinprotease des hepatitis c virus |
AR029851A1 (es) | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
SV2003000617A (es) * | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
US6846806B2 (en) | 2000-10-23 | 2005-01-25 | Bristol-Myers Squibb Company | Peptide inhibitors of Hepatitis C virus NS3 protein |
CN100391967C (zh) | 2000-11-20 | 2008-06-04 | 布里斯托尔-迈尔斯斯奎布公司 | 丙型肝炎三肽抑制剂 |
US6727366B2 (en) | 2000-12-13 | 2004-04-27 | Bristol-Myers Squibb Pharma Company | Imidazolidinones and their related derivatives as hepatitis C virus NS3 protease inhibitors |
AU2002230763A1 (en) | 2000-12-13 | 2008-01-03 | Bristol-Myers Squibb Pharma Company | Inhibitors of hepatitis c virus ns3 protease |
GB0107924D0 (en) | 2001-03-29 | 2001-05-23 | Angeletti P Ist Richerche Bio | Inhibitor of hepatitis C virus NS3 protease |
JP4455056B2 (ja) * | 2001-07-11 | 2010-04-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | 架橋二環式セリンプロテアーゼ阻害剤 |
AU2002348414B2 (en) * | 2001-10-24 | 2009-10-01 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine protease, particularly hepatitis C virus NS3-NS4A protease, incorporating a fused ring system |
CA2369970A1 (en) * | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
CN100381440C (zh) * | 2002-04-11 | 2008-04-16 | 沃泰克斯药物股份有限公司 | 丝氨酸蛋白酶、特别是丙型肝炎病毒ns3-ns4蛋白酶的抑制剂 |
US20050075279A1 (en) * | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
EP1590442A4 (en) | 2003-02-07 | 2007-07-18 | Enanta Pharm Inc | MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS |
DE10315645B4 (de) | 2003-04-04 | 2005-07-14 | Zf Boge Elastmetall Gmbh | Hydraulisch dämpfendes Gummibuchsenlager für vertikale Montage |
ATE547412T1 (de) * | 2003-04-11 | 2012-03-15 | Vertex Pharma | Inhibitoren von serinproteasen, insbesondere hcv- ns3-ns4a-protease |
TW200510391A (en) * | 2003-04-11 | 2005-03-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
AU2004233757B2 (en) | 2003-05-01 | 2007-08-02 | The Procter & Gamble Company | Striped liquid personal cleansing compositions containing a cleansing phase and a separate benefit phase comprising a water in oil emulsion |
EA009295B1 (ru) * | 2003-05-21 | 2007-12-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Соединения в качестве ингибиторов вируса гепатита с |
US7109172B2 (en) * | 2003-07-18 | 2006-09-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
MY148123A (en) * | 2003-09-05 | 2013-02-28 | Vertex Pharma | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
AR045769A1 (es) * | 2003-09-18 | 2005-11-09 | Vertex Pharma | Inhibidores de las serina proteasas, particularmente, la proteasa ns3-ns4a del vhc (virus hepatitis c) |
AU2004282148A1 (en) * | 2003-10-10 | 2005-04-28 | Vertex Pharmaceuticals Incoporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
JP2008505849A (ja) * | 2004-02-04 | 2008-02-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼ、特に、hcv、ns3−ns4aプロテアーゼの阻害剤 |
AR055395A1 (es) * | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
-
2004
- 2004-10-08 AU AU2004282148A patent/AU2004282148A1/en not_active Abandoned
- 2004-10-08 RU RU2006115558/04A patent/RU2006115558A/ru not_active Application Discontinuation
- 2004-10-08 CN CN201010183514A patent/CN101857631A/zh active Pending
- 2004-10-08 NZ NZ546663A patent/NZ546663A/en not_active IP Right Cessation
- 2004-10-08 EP EP04794554.8A patent/EP1692157B1/en active Active
- 2004-10-08 TW TW093130680A patent/TW200528472A/zh unknown
- 2004-10-08 MX MXPA06004006A patent/MXPA06004006A/es active IP Right Grant
- 2004-10-08 EP EP10183579A patent/EP2361925A1/en not_active Withdrawn
- 2004-10-08 JP JP2006534377A patent/JP2007532474A/ja active Pending
- 2004-10-08 KR KR1020117029638A patent/KR20120010278A/ko not_active Application Discontinuation
- 2004-10-08 WO PCT/US2004/033238 patent/WO2005037860A2/en active Application Filing
- 2004-10-08 KR KR1020067006901A patent/KR20060130027A/ko not_active Application Discontinuation
- 2004-10-08 CA CA002541634A patent/CA2541634A1/en not_active Abandoned
- 2004-10-12 US US10/964,214 patent/US7208600B2/en not_active Expired - Fee Related
-
2006
- 2006-04-09 IL IL174863A patent/IL174863A0/en unknown
- 2006-05-10 NO NO20062101A patent/NO20062101L/no unknown
-
2007
- 2007-03-09 US US11/716,248 patent/US8039623B2/en not_active Expired - Fee Related
-
2011
- 2011-08-18 JP JP2011179106A patent/JP2011246487A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20060130027A (ko) | 2006-12-18 |
MXPA06004006A (es) | 2006-06-28 |
WO2005037860A3 (en) | 2005-11-10 |
US20070161789A1 (en) | 2007-07-12 |
US20050137140A1 (en) | 2005-06-23 |
NZ546663A (en) | 2010-01-29 |
JP2007532474A (ja) | 2007-11-15 |
TW200528472A (en) | 2005-09-01 |
EP2361925A1 (en) | 2011-08-31 |
US8039623B2 (en) | 2011-10-18 |
US7208600B2 (en) | 2007-04-24 |
IL174863A0 (en) | 2008-02-09 |
CA2541634A1 (en) | 2005-04-28 |
WO2005037860A2 (en) | 2005-04-28 |
NO20062101L (no) | 2006-07-05 |
KR20120010278A (ko) | 2012-02-02 |
AU2004282148A1 (en) | 2005-04-28 |
EP1692157B1 (en) | 2013-04-17 |
JP2011246487A (ja) | 2011-12-08 |
EP1692157A2 (en) | 2006-08-23 |
CN101857631A (zh) | 2010-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2006115558A (ru) | Ингибиторы сериновых протеаз, особенно hcv ns3-ns4a протеазы | |
RU2006105002A (ru) | Ингибиторы сериновых протеаз, в частности, нс-3-нс4а протеазы | |
RU2006110934A (ru) | 2-амидо-4-арилокси-1-карбонилпирролидиновые производные в качестве ингибиторов серинпротеаз, в частности, протеазы ns3-ns4a hcv | |
JP2007532474A5 (US08039623-20111018-C00046.png) | ||
RU2004133044A (ru) | Ингибиторы сериновых протеаз, в частности, протеазы ns3-ns4a hcv | |
RU2008108024A (ru) | Ингибиторы серинпротеазы | |
JP2005535574A5 (US08039623-20111018-C00046.png) | ||
WO2005035525B1 (en) | 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
CN100402549C (zh) | 桥连二环的丝氨酸蛋白酶抑制剂 | |
RU2010135497A (ru) | Ингибирование протеазы ns3-ns4 вируса hcv | |
JP4806154B2 (ja) | セリンプロテアーゼ、特にc型肝炎ウイルスns3プロテアーゼのインヒビター | |
ES2381548T3 (es) | Inhibidores de serina proteasas, particularmente de la proteasa VHC NS3-NS4A | |
AU721079B2 (en) | Peptidyl heterocycles useful in the treatment of thrombin related disorders | |
EP1730167B1 (en) | Macrocyclic peptides active against the hepatitis c virus | |
JP5049788B2 (ja) | ウイルス感染症を処置するためのアンドログラフォライド(andrographolide)誘導体 | |
JP2007504251A5 (US08039623-20111018-C00046.png) | ||
AR045769A1 (es) | Inhibidores de las serina proteasas, particularmente, la proteasa ns3-ns4a del vhc (virus hepatitis c) | |
MX2011006239A (es) | Analogos ciclicos de peptido de 4-amino-4-oxobutanoilo, inhibidores de replica viral. | |
KR20000049263A (ko) | 세린 프로테아제, 특히 c형 간염 바이러스 ns3 프로테아제의억제제 | |
JP2009506078A5 (US08039623-20111018-C00046.png) | ||
JP2006505618A (ja) | Hcvセリンプロテアーゼの有効な阻害剤 | |
EA007739B1 (ru) | Гетероциклические трипептиды в качестве ингибиторов вируса гепатита с | |
WO2005077969A3 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
EA022118B1 (ru) | Ингибиторы протеазы hcv | |
CA2747636A1 (en) | Hcv ns3 protease inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20071211 |